Takeda admits running bad ads

Share this article:

Takeda's chief executive admitted that his company used “inappropriate expressions” in promotions of its blood pressure drug Blopress, reports the Wall Street Journal. The Journal notes that the CEO's statement comes after Japan's health ministry said it was going to examine the company's advertisements which used a graph that did not align with clinical trial results that compared Blopress and Pfizer's Norvasc.

The Journal says the company also “admitted using expressions in its ads that could potentially lead to misunderstanding that Takeda's drug was more effective than the rival product.”

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.